EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer

Ofra Novoplansky, Avital B Shnerb, Divyasree Marripati, Sankar Jagadeeshan, Raghda Abu Shareb, Cristina Conde-López, Jonathan Zorea, Manu Prasad, Talal Ben Lulu, Ksenia M Yegodayev, Chen Benafsha, Yushi Li und 6 weitere

Molecular Oncology · 2023

DOI: 10.1002/1878-0261.13500 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Ofra Novoplansky und 17 weiteren Autor:innen. Beteiligte Einrichtung: The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel. Hauptthemen laut MEDLINE: Phosphatidylinositol 3-Kinase, Head and Neck Neoplasms. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDCR NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blocking the mitogen‐activated protein kinase (MAPK) pathway with the MEK1/2 inhibitor trametinib has produced promising results in patients with head and neck squamous cell carcinoma (HNSCC). In the current study, we showed that trametinib treatment leads to overexpression and activation of the epidermal growth factor receptor (EGFR) in HNSCC cell lines and patient‐derived xenografts. Knockdown of EGFR improved trametinib treatment efficacy both in vitro and in vivo . Mechanistically, we demonstrated that trametinib‐induced EGFR overexpression hyperactivates the phosphatidylinositol 3‐kinase (PI3K)/AKT pathway. In vitro , blocking the PI3K pathway with GDC‐0941 (pictilisib), or BYL719 (alpelisib), prevented AKT pathway hyperactivation and enhanced the efficacy of trametinib in a synergistic manner. In vivo , a combination of trametinib and BYL719 showed superior antitumor efficacy vs. the single agents, leading to tumor growth arrest. We confirmed our findings in a syngeneic murine head and neck cancer cell line in vitro and in vivo . Taken together, our findings show that trametinib treatment induces hyperactivation of EGFR/PI3K/AKT; thus, blocking of the EGFR/PI3K pathway is required to improve trametinib efficacy in HNSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphatidylinositol 3-KinaseHead and Neck NeoplasmsHumansAnimalsMiceSquamous Cell Carcinoma of Head and NeckProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesSignal TransductionErbB ReceptorsCell Line, TumorThiazolesPyridonesPyrimidinones

Stichwörter der Autor:innen

PI3K and EGFR signalingTrametinibdrug resistancehead and neck cancer

Substanzen

Phosphatidylinositol 3-KinaseProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesErbB ReceptorsAlpelisibThiazolestrametinibPyridonesPyrimidinonesEGFR protein, human

Autor:innen und Institutionen

  • The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Division of Radiooncology-Radiobiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Department of Chemical Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Department of Biochemistry, University of Oxford, Oxford, UK.
  • School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin, China.
  • Immunogenomics and Precision Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Dexin Kong, Moshe Elkabets

Förderung

  • NCI NIH HHS
  • NIDCR NIH HHS
  • NIH HHS
  • Israel Science Foundation
  • National Institutes of Health
  • Defense Human Resources Activity

Zitieren

APA

Novoplansky, O., Shnerb, A. B., Marripati, D., Jagadeeshan, S., Abu Shareb, R., Conde-López, C., Zorea, J., Prasad, M., Ben Lulu, T., Yegodayev, K. M., Benafsha, C., Li, Y., Kong, D., Kuo, F., Morris, L. G. T., Kurth, I., Hess, J., & Elkabets, M. (2023). Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.13500

Vancouver

Novoplansky O, Shnerb AB, Marripati D, Jagadeeshan S, Abu Shareb R, Conde-López C, et al. Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer. Molecular Oncology. 2023. doi:10.1002/1878-0261.13500

BibTeX
@article{Novoplansky2023,
  author = {Novoplansky, Ofra and Shnerb, Avital B and Marripati, Divyasree and Jagadeeshan, Sankar and Abu Shareb, Raghda and Conde-López, Cristina and Zorea, Jonathan and Prasad, Manu and Ben Lulu, Talal and Yegodayev, Ksenia M and Benafsha, Chen and Li, Yushi and Kong, Dexin and Kuo, Fengshen and Morris, Luc G T and Kurth, Ina and Hess, Jochen and Elkabets, Moshe},
  title = {Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer},
  journal = {Molecular Oncology},
  year = {2023},
  doi = {10.1002/1878-0261.13500}
}
Kostenlos starten →